Attendo Targets Annual EBITA Growth Above 10%
Bitget2026/11/06 06:02- Attendo's growth model supports annual EBITA growth above 10%, driven by new capacity, acquisitions and operational improvements.
- New beds are expected to contribute average annual growth of 2-3%; occupancy is targeted to improve 1 percentage point annually.
- Expected openings total 652 places over the next 12 months, compared with 327 opened over the preceding 12 months.
- Currently, 885 places are under construction as the group increases investment in new capacity.
- Third-quarter 2026 lease-adjusted EBITA rose to SEK 557 million from SEK 482 million, primarily driven by Scandinavia.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
